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Abstract 
Background: Non-pharmacological ventricular rate control in atrial fibrillation (AF) 
without producing atrioventricular block (AVB) remains a clinical challenge. We 
investigated the hypothesis that autologous dermal fibroblast (ADF) injection into the AV 
nodal area (AVNA) would reduce ventricular response during AF without causing AVB. 
Methods and Results: Fourteen pigs underwent electrophysiology study before, 
immediately and 28 days after ~200 million cultured ADFs (n=8) or saline (n=6) were 
injected under electroanatomical guidance in the AVNA, with continuous 28-day ECG 
recording. In the ADF group at 28 days post-injection there were prolongations of PR 
interval (after vs. before: 130±13msec vs. 113±14msec, P=0.04), of AH interval during 
both sinus rhythm (92±13msec vs. 76.8±8msec, P<0.01) and atrial pacing at 400ms 
102±13msec vs. 91±9msec, P<0.01), and of AV node Wenckebach cycle length 
(230±19mec vs. 213±24msec, P<0.01), with no changes in the control group.  The RR 
interval during induced AF 28 days after injections was 24% longer in ADF-treated 
group compared to controls (488±120msec vs. 386±116msec, P<0.001).  Histological 
analysis revealed presence of ADF-labeled cells in the AVNA at 28 days.  Transient 
accelerated junctional rhythm during injections, and transient nocturnal Mobitz I AV 
conduction occurred early post-injection in both groups.   
Conclusion: Cells survived for 4 weeks and significantly slowed AV conduction and 
ventricular rate in acutely induced AF.  Critically, despite a large number of injections in 
the AVNA and marked effects on AV conduction, AVB did not occur. Further studies are 
necessary to determine the clinical feasibility and safety of this strategy for ventricular 
rate control in AF.  
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INTRODUCTION: 
Drug treatment to maintain long-term sinus rhythm or achieve ventricular rate control in 
atrial fibrillation (AF) is limited by lack of efficacy or intolerance of side effects1, 2.  Non-
pharmacological approaches3, 4 such as pulmonary vein isolation are effective but this is 
not practicable or appropriate for all patients. Several randomized controlled clinical 
trials5-7 have shown that ventricular rate control in patients with atrial fibrillation can be 
an effective therapeutic approach, with outcomes in some patient groups that are 
comparable to strategies for maintenance of sinus rhythm. Rate control in AF therefore 
remains an appropriate and common palliative strategy, and for symptomatic patients 
when all pharmacological and other non-pharmacological approaches have failed, AV 
node ablation is a well-established and widely practiced technique8, achieving control of 
symptoms in the majority of patients, but requires permanent pacemaker implantation. 
Previously, various strategic approaches to attempt AV node modification to control 
rather than abolish AV conduction have all been shown to have prohibitive risk of 
complete AV block,9, 10 and are therefore rarely attempted in current clinical practice. 
Among the advances in the area of cell therapy11-14, multiple cell types have been used 
for myocardial repair and regeneration15-18 including  restoration of conduction in 
experimental models19, 20. Cellular therapies have the potential to either enhance or block 
electrical conduction of the heart, 21, 22 and although  dermal fibroblasts injected in the 
atrioventricular node area have been shown to modify conduction velocity,21 the clinical 
therapeutic goal in AF is not that of slowing AV nodal conduction, but of controlling 
ventricular response rate.  The aim of this study was to address the hypothesis that 
injections of adult autologous dermal fibroblasts (ADF) in the AV node area would 
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inhibit AV node conduction, resulting in control of ventricular response during AF 
without inducing complete AV block or evidence of fibrotic changes in the lung. 
METHODS: 
Animal Preparation:      
The protocol was consistent with federal guidelines for the care and use of laboratory 
animals and was approved by the Institutional Animal Care and Use Committee of the 
Saint Joseph’s Translational Research Institute. Fourteen juvenile farm pigs weighing 
48.7±10.1 Kg were enrolled into the study. Anesthesia was induced by an intramuscular 
injection of a combination of 2 to 4mg/Kg of telazol, 4mg/Kg of ketamine and 2mg/Kg of 
xylazine, followed by intubation and general anesthesia induced and maintained using 
inhalant isoflurane (~1.5-2.5% in O2) . 
Autologous Dermal Fibroblast Preparation 
The groin regions were shaved, scrubbed and draped. A 6 x 2 cm sample of skin was 
harvested. The tissue was minced and digested in 0.25% Trypsin-EDTA for 1h at 37oC. 
Dulbecco’s modified eagles medium (DMEM) containing 15% fetal bovine serum (FBS) 
was added then digest was filtered through 100m strainer. Cells were washed twice with 
phosphate buffered saline (PBS) and the final cell pellet was re-suspended in DMEM 
with 10% FBS with Penicillin/Streptomycin (1%) and placed in culture at 37oC with 5% 
CO2. Fibroblasts were grown to 80% confluence then passaged (22). Passage 2-4 was 
used for cell injections. Prior to injection, fibroblasts were labeled with CM–DiI 2l/ml 
(Invitrogen, Carlsbad, CA). Cell number and viability was determined using the Trypan 
blue dye exclusion method before injection.   
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Electrophysiologic Study: 
Standard quadripolar EP catheters (Cordis, 6F) were inserted through the right and/or left 
femoral veins and advanced to the right atrial (RA), right ventricular apex (RVA), 
coronary sinus and His bundle positions under fluoroscopic guidance. The electrodes 
were connected to an EP-3 WorkMate® system (EP MedSystems, Inc., Mount Arlington, 
NJ, U.S.A.), and standard electrophysiological study with programmed stimulation was 
performed to determine PR, AH and HV intervals, AV node Wenckebach and RR 
intervals during AF induced by rapid RA pacing. PR interval was determined as the time 
interval between the P wave onset and QRS onset on the surface ECG. AH interval was 
determined as the time interval between the initial atrial deflection to the initial H 
deflection recorded in the His bundle electrogram, and was measured during sinus 
rhythm and atrial pacing at 400, 500, and 600msec drive cycle length by using 2.0msec 
square pulses at twice diastolic pacing threshold. HV interval was determined as the time 
interval between the initial H deflection recorded in the His bundle electrogram and the 
earliest deflection of the QRS complex on the surface ECG. The AV node Wenckebach 
cycle length was determined by decremental pacing from RA (progressive reduction of 
pacing cycle length, translating into faster pacing rates) at twice the diastolic pacing 
threshold until anterograde type I second-degree AV block (Wenckebach) occurred.  The 
above EP measurements were performed before injections, immediately after injections 
and at post injection time point of 28 days. AF was induced at follow-up (28 days) by RA 
pacing at a cycle length of 100msec at 2.0msec square pulses and current 10.0mA, and 
sustained for a variable period after cessation of pacing, during which ten consecutive RR 
intervals during AF were used to calculate ventricular rate. 
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Autologous Dermal Fibroblast Injections: 
Eight pigs received cell injections and six pigs received saline solution as a control.   
An RA geometry was made with a 4mm tip eletroanatomical mapping catheter (Biosense 
Webster, Diamond Bar, CA, U.S.A.) with a filling threshold of 15mm, marking the 
positions of the His bundle and the ostium of coronary sinus (CARTOTM 4.0 system, 
Biosense, Diamond Bar, CA, U.S.A.).  A Myostar catheter (Biosense Webster, Diamond 
Bar, CA, U.S.A.) - a deflectable CARTO-compatible injection catheter, was then used for 
marking the locations of the multiple injections on the RA geometry. The Myostar 
catheter has an adjustable needle depth.  Preliminary bench testing had determined the 
ideal cell concentration to maximize viability and the optimal volume of each injection 
that could be retained in an ex-vivo myocardial preparation. Based on these preliminary 
studies (data not shown), the yield from the fibroblast cell cultures was diluted to a 
volume of 50ml for an injection volume of 0.8ml delivered by indeflator pressurized to 
20 atm, resulting in ~60 injections per case.  The Myostar is deflectable and designed to 
provide support for needle penetration on deployment, and preliminary in vivo studies 
using radiopaque contrast in the injectate confirmed tissue penetration and contrast 
retention, and 2mm as being an optimal needle-depth setting for the purposes of injection 
in the region of the triangle of Koch in this study (data not shown).   
Guided by the RA geometry, multiple 0.8ml injections of a total of 50ml of ADF or 
saline were delivered along the slow and fast pathway regions around the AV node.  
Although initial injections focused on the inputs to AV node, the large number of 
injections extended to the region of confluence of slow and fast pathways, and therefore 
the region of the compact AV node, which was not deliberately avoided.   In each 
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position, the needle was deployed and the interval between each indeflator injection was 
approximately 60 seconds. The sites of injections were tagged on the CARTO map 
(Figure 1). After injections, a trans-thoracic echocardiogram (Acuson, Siemens, 
Mountain view, CA, U.S.A.) was performed to exclude complications and evaluate atrial 
and ventricular form and function. 
 
Preliminary bench testing had determined the ideal cell concentration to maximize 
viability and the optimal volume of each injection that could be retained in an ex-vivo 
myocardial preparation. Based on these preliminary studies (data not shown), the yield 
from the fibroblast cell cultures was diluted to a volume of 50ml for an injection volume 
of 0.8ml delivered by indeflator pressurized to 20 atm, resulting in ~60 injections per 
case.  The Myostar is deflectable and designed to provide support for needle penetration 
on deployment, and preliminary in vivo studies using radiopaque contrast in the injectate 
confirmed tissue penetration and contrast retention, and 2mm as being an optimal needle-
depth setting for the purposes of injection in the region of the triangle of Koch in this 
study (data not shown).   
 
Transmitter Implant and ECG Monitoring: 
After completing injections and EP evaluation, animals underwent implantation of a 
telemetry transmitter (TA10CTA-D70, DSI Systems™, Data Sciences International Inc, 
St. Paul, MN, U.S.A.) in the subcutaneous space of the abdomen for continuous telemetry 
ECG monitoring and recording over the ensuing 4 weeks. On full disclosure and 
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examination of all ECG recording, the PR interval  at its longest and any changes 
indicative of AV block or other cardiac arrhythmia during each period of 24 hours were 
reported. 
Restudy and Histology: 
At 28 days after injections, CARTO mapping and EP studies were repeated. Animals 
were euthanized; the heart and the lungs were harvested and the injected area 
corresponding to Koch’s triangle encompassing the AV node region was dissected for 
histological analysis (Figure 2). Samples were divided into 3 pieces and each piece was 
further divided into 3 sections where one was fixed in 10% buffered formalin, embedded 
in paraffin, 5m sections cut and stained with hematoxylin-eosin for assessment of 
overall cellularity and Verhoeff-Masson for collagen deposition. The other two sections 
were processed for frozen sectioning to identify CM- DiI positively labeled ADF. Frozen 
sections were cut and counterstained with 4', 6-diamidino-2-phenylindole (DAPI, Sigma, 
St. Louis, MO) to highlight cell nuclei. Images were acquired using epifluorescence 
microscopy (Nikon Eclipse E400, Japan). 
Data analysis: 
Data are expressed as mean ± standard deviation. Student’s t-tests were performed in 
order to compare continuous variables with normal distribution. Paired t-tests were used 
to compare repeated measurements in the same group. The non-parametric test of Mann-
Whitney was used for comparison between those samples without a normal distribution. 
A probability value of ≤0.05 was considered significant. For multiple repeated-measures 
comparisons, 2-way ANOVA was used, using significant p value <0.05. 
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RESULTS: 
Cell Culture and Injection 
A total of 1.9 ± 0.6x108 cells were obtained from each culture (Figure 3). The average 
culture time was 27±10 days. The cell viability after CM-DiI labeling and immediately 
before injection was 96±5%. 
Injections were performed without apparent adverse effect. The number of injections was 





Brief episodes of junctional rhythm with normal QRS morphology during and 
immediately following injections were common in both groups, and resolved with return 
to sinus rhythm in the first few hours post-procedure.  For this reason, PR and AH 
interval measurements could not be consistently or reliably measured immediately after 
injections. PR and AH intervals in sinus rhythm were comparable between groups at 
baseline. A summary of measured intervals is shown in Table 1.   
During sinus rhythm at 28 days after injection there was significant prolongation of both 
the PR (130±13msec vs. 113±14msec, p=0.04) and AH (92±13msec vs. 80±7msec, 
p=0.016) intervals compared to baseline in the ADF-treated group, but not in the control 
group (Table 1).   The mean change in PR and AH intervals (ADF-treated vs control) 
were +17ms vs +9ms (p=0.04), and +12ms vs +1ms (p=0.01) respectively.  
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During fixed atrial pacing at 600, 500 and 400 msec at 28 days, AH intervals were 
significantly increased at all cycle lengths in the ADF group compared to baseline in the 
ADF-treated group but not in the control group  These findings translated into significant 
differences in AH interval between ADF-treated and control groups at all paced cycle 
lengths (Table 2). 
The ANOVA analysis showed that there were no significant variations in the measured 
HV interval at baseline, immediately post injection and at follow-up (Table 1), neither in 
the cell group (p=0.37), nor in the control group (p=0.47) 
 The AV node Wenckebach cycle length showed no difference between groups either at 
baseline (210±32msec in control group, and 213±24msec in cell group, p=0.87), and 
prolonged significantly at 28 days only in the ADF-treated group compared to baseline 
(230±19mec vs. 213±24msec, p=0.009). 
Ventricular rate during AF 
At 28 days after injection, the mean RR interval during acutely induced AF was 
~100msec longer in the ADF-treated group compared to controls (488±120msec vs. 
386±116msec, p<0.001), with no change in the control group.   
Continuous ECG Telemetry 
Real-time ECG monitoring during the 28 days of observation showed PR interval 
prolongation during the first 5-7 days after injection in both groups, then progressively 
returning to baseline levels in the control group. The ADF group, however, presented a 
partial return of PR interval but not back to baseline levels and remained steadily elevated 
for the ensuing period of observation (see Figure 4). In one animal in ADF-treated group, 
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two isolated episodes of nocturnal second-degree AV block occurred on the second and 
third days of observation (Figure 5).  Neither late complete AV block nor change in HV 
intervals occurred in either group. 
 Necropsy and Histological Findings: 
No evidence of perforation, thrombosis or pericarditis was noted during macroscopic 
analysis. Under light microscope, small isolated concentrations of scant mononuclear 
cells were found in the perinodal myocardium in the ADF-treated group, probably 
representing mild localized inflammation, (Figure 6) with no evidence of any major 
inflammatory response. Under epifluorescent microscopy, only in the ADF group, CM-
DiI-labeled cells were identified (Figure 7). The presence of CM-DiI at the membrane 
surface concordant with the DAPI counterstaining in the nuclei confirms cell viability at 
the time of sacrifice. Extensive examination of the lungs showed no macroscopic or 
microscopic abnormalities. 
 
DISCUSSION:         
The findings of this study are that ADFs can be safely injected into the AV nodal region, 
resulting in slowing of AV nodal conduction and of the ventricular response rate in 
acutely induced AF in pigs.  Importantly, despite a deliberately large number of 
injections, no animal developed complete AV block in the first 28 days, and only one 
animal had two brief episodes of transient nocturnal second degree AV block (narrow 
QRS) during the first two days after injection. No attempt was made to avoid the compact 
AV node, and that some of the injections will have been directly in to this region was 
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evident from the acute detectable effects on AV nodal function (prolongation of AH and 
PR intervals) in the absence of AV block up to 28 days, suggests a margin of safety that 
is unique among all previous attempted strategies for AV nodal modification and a highly 
promising proof of concept. 
 
Transient junctional rhythm and prolongation of the PR interval during injections were 
both observed, but always settled with return to sinus rhythm and normalization of the PR 
interval within a few hours after completion of the injections. The frequency, timing and 
consistency of these transient changes in rhythm in both groups would implicate 
mechanical trauma of the injection procedure and not the later biological response to 
ADF transplantation.  
While the initial changes can be explained by a simple mechanical effect, the late 
changes seen only in the ADF group - the prolongation of the AH interval, the 
Wenckebach cycle length and, most importantly with respect to potential clinical 
applicability, prolongation of the mean R-R interval in acutely induced AF, result from 
the late biological effect of the injected ADF cells.  
Dermal fibroblasts are mesenchymal cells that are readily isolated and cultured in the 
laboratory and play an important role in tissue engineering and regeneration, including 
the treatment of burns, chronic venous ulcers and several other clinical applications in 
dermatology and plastic surgery23-27.  Although previous studies have reported the effects 
of ADF on myocardial conduction, including the AV node and focusing principally on 
conduction velocity (20-27), no previous studies have addressed the critical safety 
concern of high-grade AV block excluded by the extended and continuous rhythm 
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monitoring in the present study.  The putative mechanisms for the effect of the 
transplanted ADFs in retarding AV conduction include collagenous interruption of the 
myocardial syncytium and cell separation, and myocyte-fibroblast gap-junctional 
coupling providing an alternative sink for charge transfer between cardiac myocytes28. 
We have shown previously that injection of autologous dermal fibroblasts in chronic 
myocardial infarction can potentially lead to stabilization of arrhythmogenic burden in a 
swine model, preventing development of both induced and spontaneous ventricular 
arrhythmias (29).  Kizana et al29 reported that fibroblasts can be genetically modified to 
produce excitable cells capable of electrical coupling, with additional potential for 
treating cardiac conduction defects. 
In the present study, histological examination showed that after 4 weeks there was no 
significant inflammatory or major fibrotic response in either the perinodal myocardium or 
the lungs, which will have received significant ADF overspill from injections, indicating 
that despite a different tissue of origin, autologous cells for ventricular rate control in 
atrial fibrillation remains a realistic proposition requiring further investigation.  
 
Clinical application 
Clinical trials continue to address the question of rate versus rhythm control in atrial 
fibrillation, and some studies indicate that in certain populations of patients, a rate control 
strategy may be preferable. Although the strategy of rhythm control has benefited from 
ablation and novel anti-arrhythmic drugs, therapeutic options in rate control have 
remained largely unchanged for decades and expose patients to drugs frequently with 
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limited efficacy and side effects or the need for permanent ventricular pacing after AV 
node ablation.   
Specifically, attempts at AV nodal modification, such as with selective RF, cryo-, or 
other destructive ablation with the intent to avoid complete abolition of AV nodal 
conduction and retain normal ventricular activation sequence, have proven unsuccessful 
because of an unacceptable incidence of AV block. Although of limited clinical utility as 
a measure of efficacy, when assessing safety the PR and AH intervals were very 
important to measure at the time of injection because this study was designed specifically 
to give a very large number of injections in and around the AVN in an attempt to cause 
AV block – failure to achieve which, coupled with the early modest changes in AH and 
PR, is reassuring of a much wider margin of safety of critical importance to this proof of 
concept compared with previous interventions to modify AVN, including RF and Cryo. 
Autologous fibroblast injection that can safely be delivered transvenously to slow 
ventricular rate in AF as an alternative to long term drug treatment, is a compelling 
treatment strategy of potential high impact requiring further investigation. 
 
Before progressing to clinical use in humans, further studies will be necessary to 
determine the ideal cell concentration, volume and total number of cells or injections per 






Despite the small numbers of animals, the lasting and beneficial effects on AV 
conduction indicate a robust treatment effect for the 4 weeks of follow up.  Further 
studies will be required to investigate more long-term effects in progressing towards 
clinical application and to better clarify the specific mechanism involved in the 
atrioventricular conduction delay induced by ADF. The atrial fibrillation in this study 
was acutely induced episodes, and may differ from more naturally occurring AF.  
The present study did not evaluate the effect of isoproterenol challenge acutely after 
injections because the expected effects of this intervention on AVN conduction, as 
proved to be correct, took days to evolve, and procedural testing would not therefore have 
been informative.  In fact, acutely the main question was that of safety (AV block) rather 
than efficacy, and to have given isoproterenol may potentially have masked this.   In 
follow up, we considered the telemetered ventricular rate monitoring that was performed 
in this study to be the most informative measure.   
 
Conclusions 
Transplantation of ADFs in the AV node area in pigs is feasible, safe and slows 
ventricular rate in acutely induced AF.  Despite a large number of injections, complete 
AV block did not occur.  These results encourage further investigation of a novel strategy 
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Figure 1: Three- dimensional mapping of right atrium with CARTO 4.0 mapping system. 
His bundle (orange dot) and CS ostium (pink dot) was marked on the map. Injections 
were performed along the slow and fast pathways around peri-nodal region (red dots).  
Figure 2: RA septum visualization during necropsy in one animal. The dotted lines 
represent the histologic sections – A1, A2 and A3 were submitted to formalin fixation for 
24 hours before embedding in paraffin; sections A2, B2 and C2 were frozen after use of 
fixation and sections A3, B3 and C3 were frozen without fixative. F. Ovalis = fossa 
ovalis; C.S. ostium = coronary sinus ostium. 
Figure 3: Pig autologous skin fibroblasts in culture Panel A: Pig ADF culture at 2 days, 
100X magnification. Panel B: Pig ADF culture at 28 days, 100X magnification. 
Figure 4: PR interval on real-time ECG during 28 days of observation period   
Figure 5: Presence of second degree AV block during real-time ECG monitoring in one 
animal at 2 days after ADF injections  
Figure 6:  Right atrium histology. A, Site of injection stained with H&E. Arrows show 
sites of injection (4X); B, Section shown in panel A under 10X magnification; C, Site of 
injection stained with Masson Verhoeff. Arrows show the clusters of cells and D, shows 
the same area as panel C under 10X magnification. 
Figure 7: Identification of ADF labeled with CM-DiI (A) and nuclei counterstaining with 
DAPI (B) 28 days after injection. The white arrows represent the edge of a site of  the 

































Table 1. Basic interval measurements at baseline, post injection and at follow-up, expressed in 
miliseconds 













PR 113 ± 14 163 ± 17 130 ± 13 0.04* 113 ± 14 146 124 ± 12 0.16* 
AH 80 ± 7 113 ± 18 92 ± 13 0.02* 75 ± 9 100 ± 25 76 ± 8 0.83* 
HV 34± 3 33± 2 33 ± 1 0.37** 31 ± 4 32 ± 2 32 ± 4 0.47** 
*Statistical comparison between 28-day and baseline 






Table 2. AH interval measurements, expressed in miliseconds; and at pacing cycle length of 400, 500 
and 600 ms 
 ADF treated Control 
 Baseline 28-day p value Baseline 28-day p value 
400 ms 91 ± 9  102 ± 13 <0.01 87 ± 14 88 ± 12 0.47 
500 ms 84 ± 9 96 ± 15 0.02 85 ± 15 82 ± 9 0.83 
600 ms 82 ± 8 93 ± 16 0.04 81 ± 15 78 ± 10 0.61 
 
